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GM2 gangliosidosis is a family of three genetic neurodegenerative disorders caused by the accumulation of
GM2 ganglioside (GM2) in neuronal tissue. Two of these are due to the deficiency of the heterodimeric (a–b),
‘‘A’’ isoenzyme of lysosomal b-hexosaminidase (HexA). Mutations in the a-subunit (encoded by HEXA) lead
to Tay-Sachs disease (TSD), whereas mutations in the b-subunit (encoded by HEXB) lead to Sandhoff
disease (SD). The third form results from a deficiency of the GM2 activator protein (GM2AP), a substrate-
specific cofactor for HexA. In their infantile, acute forms, these diseases rapidly progress with mental and
psychomotor deterioration resulting in death by approximately 4 years of age. After gene transfer that
overexpresses one of the deficient subunits, the amount of HexA heterodimer formed would empirically be
limited by the availability of the other endogenous Hex subunit. The present study used a new variant of
the human HexA a-subunit, l, incorporating critical sequences from the b-subunit that produce a stable
homodimer (HexM) and promote functional interactions with the GM2AP– GM2 complex. We report the
design of a compact adeno-associated viral (AAV) genome using a synthetic promoter–intron combination
to allow self-complementary (sc) packaging of the HEXM gene. Also, a previously published capsid mu-
tant, AAV9.47, was used to deliver the gene to brain and spinal cord while having restricted biodis-
tribution to the liver. The novel capsid and cassette design combination was characterized in vivo in TSD
mice for its ability to efficiently transduce cells in the central nervous system when delivered intrave-
nously in both adult and neonatal mice. This study demonstrates that the modified HexM is capable of
degrading long-standing GM2 storage in mice, and it further demonstrates the potential of this novel
scAAV vector design to facilitate widespread distribution of the HEXM gene or potentially other similar-
sized genes to the nervous system.
INTRODUCTION
TAY-SACHS DISEASE (TSD) is one of a group of
three lysosomal storage diseases called GM2 gang-
liosidosis, caused by defective catabolism of GM2
ganglioside (GM2). It is an autosomal recessive
neurodegenerative disease caused by mutations
in the a-subunit of the heterodimeric enzyme b-
hexosaminidase A (HexA). Sandhoff disease (SD)
is caused by mutations in the b-subunit of HexA.
Both subunits can also form functional homo-
dimers, HexS (a–a) and HexB (b–b), which in
humans cannot significantly turn over GM2. HexS
is unstable and physiologically less significant,
whereas HexB is highly stable and can degrade
some neutral glycolipids, oligosaccharides, and ar-
tificial substrates. The enzyme HexA (a–b) requires
a substrate-specific cofactor, called GM2 activator
protein (GM2AP), to efficiently degrade GM2. Muta-
tions to the gene encoding GM2AP lead to another
rare variant of GM2 gangliosidosis, the AB-variant
form. The characteristic histopathological feature of
these diseases is the presence of swollen neurons
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and neuronal distortion throughout the nervous
system caused by accumulated GM2. TSD and SD
are clinically variable, with severe forms showing
profound mental retardation and death within 2–3
years of birth.1 Heterogeneity of the disease re-
garding severity of clinical signs and age of onset
can be attributed to the level of residual HexA ac-
tivity allowed by different mutations. It has been
estimated that only between 10 and 15% of normal
HexA activity is needed to prevent GM2 accumula-
tion.2 At present, there are no effective treatment
options available for these diseases.
To study the disease mechanisms and to test
various therapeutic approaches,mousemodels have
been developed for both these diseases. The mouse
model for TSD, developed by the targeted disruption
of thehexa gene encoding the a-subunit,3–5 has no or
a mild behavioral phenotype but displays many of
the neuropathological features characteristic of
TSD, in particular GM2 ganglioside accumulation.
The absence of clinical signs in TSD mice is due to
the presence of a lysosomal mouse sialidase capable
of hydrolyzing GM2 to its neutral asialo derivative,
GA2, which then interacts with HexB to be further
degraded to glucosylceramide.5,6 This alternative
metabolic pathway helps TSD mice to keep GM2 ac-
cumulation below an acutely toxic level and thereby
escape clinical symptoms. The hexb–/– mouse model
for Sandhoff disease exhibits a severe disease phe-
notype as it is deficient in both HexA and HexB and
has extensive GM2 accumulation throughout the
brain and spinal cord with a humane end point of
approximately 16 weeks of age.4,5
Several gene replacement therapies have been
tested in the mouse models for these diseases. The
heterodimeric nature of HexA, which is the only
isoenzyme capable of degrading GM2, makes the
treatment for TSD and SD more challenging. Ade-
noviral gene therapy of TSD mice, using a vector
encodingHEXA alone, when injected intravenously
produced only a slight increase in HexA (or possibly
HexS mistaken for HexA) activity in the serum,
whereas simultaneous injection of vectors encoding
both HEXA and HEXB increased the serum HexA
activity to 42% of wild-type levels in thesemice.7 SD
mice injected intracranially with a recombinant
adeno-associated viral (rAAV) vector expressing the
b-subunit, or a combination of vectors with a- and
b-subunits, showed reduction in GM2 levels and in-
creased survival.8 However, the effect of the single-
subunit vector in this study could be attributed to
higher levels of HexB and the mouse sialidase
driving the alternative metabolic pathway for
hydrolyzing GM2. A single striatal injection of a
mixture of vectors expressing the b-hexosaminidase
a- andb-subunits inSDmiceprevented theneuronal
loss in the brain.9 Cachon-Gonzalez and colleagues
reported that intracranial coinjection of rAAV vec-
tors expressing the a- and b-subunits into 1-month-
old SD mice prevented the disease pathology
throughout the brain and spinal cord, which helped
the mice survive up to 2 years.10 In that study, an
infusion of an rAAV vector encoding the b-subunit
alone resulted in detectable expression of only the
HexB isozyme. AAVrh8 vectors encoding feline a-
and b-subunits were injected intracranially into SD
cats at a 1:1 ratio, and this resulted in a significant
reduction in cerebrospinal fluid (CSF) biomarkers of
thedisease. It ultimately resulted in extension of the
life span for the treated cats.11 Intracranial stereo-
taxic infusion of a mixture of rAAV2/1a and rAAV2/
1b into 4-week-old SD mice extended the median
survival from 131 to 615 days.12
The gene replacement therapies so far discussed
all used direct injections to the brain, using viral
vectors. The possibility of translating this highly in-
vasive delivery approach into humans is problematic
simply given the size differential between the brains
of animalmodels andhumans, alongwith the limited
spread of AAV vectors from the injection site. The
emergence of AAV9 vectors for global gene transfer
into the brain and spinal cord, due to its ability to
penetrate the blood–brain barrier, has resulted in
therapeutic approaches for multiple CNS diseases
via intravascular gene delivery.13–17 Intravenous
administration of self-complementary AAV9 vectors
has been demonstrated as a viable and translatable
approach to target the CNS in mice, cats, and non-
human primates,18–21 and this approach is being
applied in a human trial for spinal muscular atrophy
(clinicaltrials.gov identifier NCT02122952). These
studies demonstrating the ability of AAV9 to achieve
widespread CNS transduction all relied on the more
efficient, self-complementary AAV (scAAV), vector
design. scAAV vectors have been shown to be greater
than 10-fold more efficient in transducing cells,
compared with traditional single-stranded AAV
(ssAAV) vectors when tested in vivo.18,22 The draw-
back of using an scAAV vector is the restricted pack-
aging capacity of approximately 2.2kb of foreign
DNA,making itdifficult topackage largergenesalong
with regulatory expression elements. In a review by
Powell and colleagues,23 they listed the relative
strength and size of various promoters and poly-
adenylation [poly(A)] signals. Among thewidely used
ubiquitous promoters, the cytomegalovirus (CMV)
early enhancer/chicken b-actin (CBA or CAGGS)
promoter (1600bp), the relatedhybrid chickenb-actin
(CBh) promoter (800bp), and the CMV enhancer/
promoter (800bp) are all too large to accommodate a
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HEX gene in an scAAV vector. Small enhancerless
promoters such as UbC, MeCP2, and GUSB could
accommodate the size of the HEX gene, but would
likely provide inadequate levels of expression. At
present, no publication has described an scAAV
vector design capable of packaging the approxima-
tely 1.6-kbHEXA orHEXB gene to treat TSD or SD.
An ideal vector capable of treating TSD and SD
would express both HEXA and HEXB genes simul-
taneously, but this would be beyond the packaging
capacity of scAAV, which is needed to achieve effi-
cient global CNS gene transfer. Therefore, there is a
conceptual advantage to creating an engineered
subunit that could bedelivered, usinga single scAAV
vector, and that could form a stable and functional
homodimer when delivered in vivo and degrade
GM2 in a GM2AP-dependent manner. The crystallo-
graphic structures of human HexA and HexB have
been elucidated in detail.24,25 Matsuoka and col-
leagues attempted to design and develop a modified
HexB reported to have GM2-degrading activity and
GM2AP-binding ability, based on the amino acid ho-
mology between the Hex a- and b-subunits.26 They
purified the modified HexB recombinant enzyme
with the altered substrate specificity, that is, the
ability to efficiently bind negatively charged sub-
strates, and an a-loop sequence for enhancing
its interaction with the GM2AP–GM2 complex.
They administered the modified HexB by in-
tracerebroventricular injection directly to the
CNS of 10-week-old SD mice and observed a re-
markable reduction inGM2 storage in the thalamus,
cerebral cortex, and also the liver. Their results
indicated that the modified HexB enzyme can func-
tion in vivo if used in enzyme replacement therapy
(ERT). However, Sinici and colleagues27 tested this
construct and another more extensive hybrid b-
subunit construct in cellulo, using Tay-Sachs cells
preloaded with a fluorescent GM2 derivative, and
found thatneithermodifiedb-subunitwascapable of
significant human GM2AP-dependent hydrolysis of
GM2. Likely, the encouraging results reported by
Matsuoka and colleagues are attributable to resto-
ration of HexB-like activity that takes advantage of
the alternative sialidase pathway in mice. As an
alternative approach to develop a hybrid subunit,
Tropak and colleagues28 designed a modified a-
subunit incorporating both the unique b-subunit
sequences required to form a stable, HexB-like,
homodimer and those sequences needed for the
homodimer to interact with the GM2AP–GM2 com-
plex. The a-active site was retained in order to
facilitate the hydrolysis of negatively charged sub-
strates, for example, GM2. This modified subunit (l)
was confirmed to form a stable dimeric enzyme,
HexM,which could bind to theGM2AP–GM2 complex,
and degrade GM2 in live human embryonic kidney
(HEK) cells rendered HEXA–/– and HEXB–/– by
CRISPR (clustered regularly interspaced short pal-
indromic repeats) gene editing. In vivo experiments
in this study further demonstrated the ability of
HexM to reduce accumulated GM2 in Tay-Sachs and
Sandhoffmice.Therefore, thishomodimerhasHexA-
like activity and can be expressed from a single gene
packageable within an scAAV vector. This construct
is discussed further in the present study.
It is important to note that systemic delivery of
AAV9 vectors results in substantially higher biodis-
tribution to the liver compared with the CNS, which
could lead to transgene-specific liver toxicity.15,29
Furthermore, some studies have reported incidence
of liver tumors with intravenous delivery of AAV9
into neonates.14,30,31 A liver-detargeted version of
AAV9with comparable levels of brainand spinal cord
transduction could be a safer reagent to treat neuro-
logical disorders. Pulicherla and colleagues32 re-
ported the generation of AAV9-derived vectors
displaying selective loss of liver tropism. One AAV9
variant, denoted as AAV9.47 with four point muta-
tions (S414N, G453D, K557E, and T582I), showed a
significant 110-fold decrease in the liver transduction
inmice injectedvia the tail veinandanalyzed4weeks
postinjection by vector DNA biodistribution and
transgene (luciferase) expression. The transduction
pattern in thebraindidnotshowanysignificantdrop,
which suggests AAV9.47 as a good candidate for glo-
bal gene delivery to the CNS via systemic injection.
In the present study, we discuss the functional
ability of the new hexosaminidase variant HexM
and the design of a novel expression cassette to
package it into an scAAV vector for in vivo applica-
tions.We show that thenovel cassette has the ability
to provide ubiquitous transduction throughout the
CNS. We provide further characterization of the
liver-detargeted AAV9.47 variant to demonstrate
its ability to transduceneurons andglia throughout
the CNS after intravenous injection into neonatal
and adult mice. We demonstrate that the HexM
homodimer is capable of degrading GM2 in a local-
ized manner when injected intracranially into
adult TSD mice, and that the scAAV9.47/HEXM
vector can mediate long-term GM2 reduction when
injected intravenously into neonatal TSD mice.
MATERIALS AND METHODS
Plasmid constructs
The plasmids carrying the transgene cassette
required for packaging into scAAV vectors were
designed for GFP, HEXA, and HEXM. This novel
GENE THERAPY VECTOR IMPROVEMENTS FOR TSD 511
design includes the combination of a short synthetic
and ubiquitous promoter derived from the JeT
promoter33 and a synthetic intron (UsP, also re-
ferred to as the JeTI promoter) along with the sim-
ian virus 40 polyadenylation signal [SV40 poly(A)]
to drive expression of the encoded gene (Fig. 1). A
Kozak consensus sequence was incorporated at the
start codon. Pilot in vitro studies showed that the
UsP expression cassette had approximately 15% of
the activity when using a CMV promoter (Supple-
mentary Fig. S1; supplementary methods and data
areavailableonlineatwww.liebertpub.com/hum).The
nucleotide sequence of the synthetic JeT promoter
and intron is provided in Supplementary Fig. S2.
The humanHEXA andHEXM genes were codon-
optimized by DNA2.0 (Menlo Park, CA). The con-
struct expressing GFP from the CBh promoter22
with the bovine growth hormone (BGH) poly(A)
was used as a reference standard for comparative
gene expression for the newly designed constructs.
Vector preparation
Recombinant AAV vectors were generated as
described,34 using proprietarymethods developedat
the University of North Carolina Gene Therapy
Center Vector Core facility (Chapel Hill, NC). The
following AAV9 or AAV9.47 vectors were produced
and used for this study: AAV9/CBh-GFP, AAV9.47/
CBh-GFP, AAV9/UsP-GFP, AAV9/UsP-HEXA, AAV9/
UsP-HEXM, AAV9.47/UsP-GFP, and AAV9.47/UsP-
HEXM. All of these were scAAV vectors. Peak frac-
tions were dialyzed in phosphate-buffered saline
(PBS) containing 5% D-sorbitol and 350mM NaCl.
Viral titerswere determined by qPCRas described.35
Mouse studies
All investigations were approved by the Uni-
versity of NorthCarolina–ChapelHill Institutional
Animal Care and Use Committee. The Tay-Sachs
disease mouse model [strain B6;129S-hexa–/–]3 and
wild-type C57BL/6 mice were purchased from the
Jackson Laboratory (Bar Harbor, ME) and bred at
the University of North Carolina.
For intravenous delivery into wild-type adult fe-
male C57BL/6 mice, 200ll of scAAV9/GFP (2·1011
VG) or AAV9.47/GFP (2·1011 VG) was injected and
expression/biodistribution was analyzed 3–4 weeks
postinjection. Adult TSD knockout mice were in-
jected via the tail veinwith scAAV9.47/GFP (5·1011
VG) in a volume of 200ll when 4–5 months old and
were analyzed 6 months postinjection.
Neonatal facial vein injections into TSD mice
were performed on postnatal days 0–2 (P0–P2), us-
ing scAAV9.47/UsP-GFP (5·1010 VG) or scAAV9.
47/UsP-HEXM (5·1010VG) inavolumeof 20ll.The
injections were carried out before the genotypes of
themicewere determined and as such included both
heterozygous and knockout mice. They were eutha-
nized when 15 months old.
Intracranial injections were performed as de-
scribed35 into 15-month-old TSD knockout mice,
using the following stereotaxic coordinates, relative
to bregma: rostral/caudal, +0.5mm (toward rostral);
left/right: left, +3mm; up/down, -4mm. These mice
received a mixture of AAV9/GFP (1·109 VG) and
either AAV9/HEXM (1·109 VG) or AAV9/HEXA
(1·109 VG) in a total volume of 1ll delivered over
10min. Two mice were injected per vector mix-
ture. They were analyzed 4 weeks postinjection.
At sacrifice, the mice were transcardially perfused
with PBS containing heparin at 1U/ml (Abraxis,
Schaumburg, IL) and samples were collected for
downstream analysis.
Immunohistochemistry
After 48hr of fixation in freshly made PBS con-
taining 4% paraformaldehyde, the entire brain and
portionsof the cervical and lumbar spinal cordswere
sectioned at 40lm, using a Leica vibrating micro-
tome. Every fifth section was processed for immu-
nohistochemistry (IHC). Sections were treated with
hydrogen peroxide to remove endogenous peroxi-
dase activity before blocking. Samples were incu-
bated for 1hr at room temperature in blocking
solution (10% goat serum, 0.1% Triton X-100,
1·PBS) and then incubated for 48–72hr at 4C in
primary antibody solution (3% goat serum, 0.1%
Triton X-100, 1·PBS, and primary antibody). Pri-
mary antibodies were as follows: rabbit anti-GFP
(diluted 1:1000; #AB3080, Millipore, Bedford, MA)
or thehumananti-GM2gangliosideantibody (diluted
1:1000; KM966, gift from Kyowa Hakko Kirin, To-
kyo, Japan). After incubating with the appropriate
Figure 1. Adeno-associated viral (AAV) construct diagrams. The expres-
sion cassette design for packaging GFP and codon-optimized versions of
human HEXA and HEXM included a novel synthetic promoter–intron com-
bination (UsP) along with the simian virus 40 polyadenylation signal (SV40
polyA) to drive expression. These elements are flanked by the mutant in-
verted terminal repeat (ITR) on the 5¢ end and the wild-type (WT) AAV2 ITR
on the 3¢ end to package into a self-complementary AAV vector. Color
images available online at www.liebertpub.com/hum
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secondary antibody for 1hr at room temperature,
color development was performed with a VECTAS-
TAINEliteABCkit (#PK-6100;VectorLaboratories,
Burlingame, CA) with 3,3¢-diaminobenzidine tetra-
chloride (DAB) (#04008; Polysciences, Warrington,
PA) substrate and nickel–cobalt intensification of
the reaction product.
DAB-processed brain sectionswere digitizedwith
a ScanScope slide scanner (Aperio Technologies,
Vista, CA). Virtual slides were viewed with the
ImageScope software package (version 10.0; Aperio
Technologies).
For the data provided in Supplementary
Fig. S3B, a region of interest was created in three
representative images of an identical cortex area of
the brain per vector treatment, and the number of
astrocytes and neurons (identified by morphology)
were manually counted. The results from two in-
dependent counters were averaged. Data are ex-
pressed as number of cells per millimeter squared.
Quantitative PCR analysis of vector genomes
Quantitative PCR (qPCR) was used for vector bio-
distribution studies. Tissue DNA was purified and
quantified as described.18 Data are reported as the
number of double-stranded GFP or HEXM DNA
molecules per two double-stranded copies of the mu-
rineLaminB2 locus, or in otherwords, the number of
vector DNA copies per diploid mouse genome.
Biochemical detection of GM2 gangliosides
Gangliosides were extracted by a modification of
a method described earlier.36 Briefly, previously
frozen murine mid-brain sections were weighed
and sonicated in 0.5ml of methanol at amplitude
15–20% for 3 ·10 sec pulses with cooling on ice
between pulses (Sonic Dismembrator model 500;
Fisher Scientific, Waltham, MA). Samples were
centrifuged for 15min at 10,000 rpm at 4C, and
0.4ml of supernatant was removed for enzyme ac-
tivity studies; the remainder was suspended (in-
cluding the pellet) up to a final volume of 1.5ml of
methanol added to 2.5ml of chloroform. Acidic gan-
gliosides were isolated using C18-E columns (Phe-
nomenex, Torrance, CA) and eluted sequentially in
2ml ofmethanol, and then in 2ml of a 1:1methanol–
chloroformmixture.Theeluatewas thenevaporated
under a stream of nitrogen, and the residue was re-
suspended in 1:1 methanol–chloroform and then
applied to an HPTLC silica gel 60 plate (Merck,
Darmstadt, Germany) by applying 10ll at a time
and drying between applications. Plates were de-
velopedwith runningbuffer (chloroform–methanol–
CaCl2, 0.22% [55:45:10]). After staining with orcinol
(Sigma-Aldrich, St. Louis, MO) and baking at 105C
for 10min, plates were immediately scanned for
subsequent spot densitometric analysis (ImageJ
software), with a mix of monosialoganglioside
standards (Matreya, Pleasant Gap, PA) alongside.
The ganglioside ratios are presented as GM2:total
gangliosides.
RESULTS
Liver-detargeted AAV9.47 capsid transduces
neural cells after intravenous administration
in adult mice
AAV9.47 capsid was engineered as described.32
It was categorized as a liver-detargeted version of
the AAV9 capsid, with a significant 110-fold de-
crease in liver transduction relative to the natu-
rally occurring AAV9 capsid. The level of overall
brain transduction was comparable to that of the
original AAV9 capsid, making it a good candidate
for targeted delivery to brain and otherCNS organs
via the intravenous route while avoiding the high
biodistribution of AAV9 to the liver. The liver-
detargeted characteristics of the AAV9.47 vector
reported previously were confirmed in our study by
a biodistribution study (Supplementary Fig. S3A).
However, previous studies did not identify which
cell types were transduced by AAV9.47 within the
CNS. In our study, we observed that the capsid
is able to transduce neural cells, predominantly
neurons, when delivered intravenously into adult
wild-typemice (Fig. 2B andSupplementaryFig. S4).
GFP expression was visible throughout various re-
gions of the brain and spinal cord. When compared
with the transduction profile of AAV9 capsid pack-
aged with the same transgene cassette containing
GFP under the control of the CBh promoter and
injected into wild-type mice (Fig. 2A), there was an
approximately 4-fold reduction in the number of
astrocytes transduced by the AAV9.47 capsid and
an approximately 50% increase in the number of
transduced neurons in the cortex (Supplementary
Fig. S3B). Overall, AAV9.47 transduced approxi-
mately 20% less cells than AAV9 in the cortex.
Synthetic UsP promoter–intron drives
ubiquitous expression in the brain
Previously, our laboratory described the use of
a modified b-actin promoter with a shortened
MVM (minute virus of mice) intron to drive sus-
tained high levels of transgene expression in
both neurons and glia throughout the CNS.22
Combined with the BGH poly(A) signal, this
scAAV construct can package a transgene of up
to approximately 1.2 kb in length. The HEXA and
HEXM transgenes are approximately 1.6 kb in
length, requiring a novel expression cassette to
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provide efficient and ubiquitous expression within
the contexts of an scAAV genome. The newly de-
signed expression cassette (Fig. 1), using the syn-
thetic UsP promoter–intron combination, paired
with the SV40 poly(A) signal, is capable of wide-
spread expression in the CNS (Fig. 2C and Sup-
plementary Fig. S4) after intravenous delivery in
wild-type mice. The intensity of GFP expression in
astrocytes is noticeably decreased for the UsP-GFP
construct, compared with the CBh-GFP construct,
when both were packaged in the AAV9 capsid.
However, the novel design has the advantage of
being capable of packaging a transgene up to ap-
proximately 1.7 kb within an scAAV vector, which
will accommodate the HEXA or HEXM transgene.
AAV9.47 capsid is capable of widespread
gene transfer to the brain after intravenous
administration in both adult and neonatal
Tay-Sachs mice
To assess the ability of the UsP construct to
mediate long-term sustained expression in the
Tay-Sachs mouse model, we packaged the newly
designed UsP-GFP construct within the AAV9.47
Figure 2. CNS transduction pattern of AAV9/CBh-GFP, AAV9.47/CBh-GFP, and AAV9/UsP-GFP after intravenous administration in wild-type mice. Adult wild-
type mice were injected intravenously with 2· 1011 vector genomes (VG) of scAAV9/CBh-GFP (A), scAAV9.47/CBh-GFP (B), or scAAV9/UsP-GFP (C) and then
were euthanized 3 weeks postinjection to assess green fluorescent protein (GFP) transduction levels in various parts of the brain and spinal cord. Scale bar:
500 lm. Insets: An additional· 5 magnification. All images are representative of at least three mice.
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capsid and injected it intravenously into adult
TSD mice at 4–5 months of age and into neonatal
mice, consisting of both TSD and their heterozy-
gous littermates, at age P0–P2. These mice were
euthanized 6 and 15 months postinjection, re-
spectively, and were analyzed for the biodis-
tribution of the AAV vector by qPCR and for CNS
transduction by IHC against GFP. As previously
reported, the vector was significantly detargeted
from the liver compared with the biodistribution
pattern of AAV9,18,32 while retaining biodistribu-
tion to the brain and spinal cord (Figs. 3A and 4A).
IHC images of the brain clearly showed that the
AAV9.47 capsid can deliver the gene to all regions
of brain and facilitate expression in neurons and
glia within the CNS of hexa–/– and hexa+/– mice,
and that this expression persisted for 15 months
(Figs. 3B and 4B).
The hexosaminidase variant, HexM, can clear
GM2 storage similar to HexA after intracranial
administration into aged Tay-Sachs mice
To directly test the expression of the new hexos-
aminidase gene variant, HEXM, to reduce long-
standing accumulated GM2 in the TSDmouse brain,
compared with that of the unmodified HEXA gene,
these were packaged into scAAV9 vectors and in-
jected stereotaxically into 15-month-old TSD mice
along with an identical titer of scAAV9/UsP-GFP
vector to track vector spread. Each experimental
Figure 3. Biodistribution and brain transduction after intravenous administration of AAV9.47/UsP-GFP in adult Tay-Sachs mice. Adult Tay-Sachs knockout
mice were injected intravenously when 4–5 months old with 5· 1011 VG of scAAV9.47/UsP-GFP and analyzed 6 months postinjection. (A) The average number
of GFP vector genomes in major organs from six mice. Error bars indicate the SEM. (B) Immunohistochemical (IHC) images from various regions of the brain
from TSD mice showing GFP expression. Scale bar: 500 lm. Insets: An additional· 5 magnification. The images are representative of four mice.
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group consisted of two animals receiving the same
vector combination. The mice were euthanized 4
weeks postinjection and the brain sections were
subjected to IHC analysis against GFP and GM2 si-
multaneously.Several paired imagesof similarbrain
regions were analyzed. The HexA-like activity was
assessed by the clearance of GM2 within the injected
region, compared with the contralateral brain
hemisphere (Fig. 5E–G). The area of AAV transduc-
tion was visualized by staining for GFP (Fig. 5A–C).
Qualitatively, a marked reduction of GM2 was ap-
parent in the areas that overlappedwith strongGFP
expression. Both b-hexosaminidase vectors were
able to degradeGM2 in the regions thatwere injected,
but complete clearance of accumulated GM2 was not
obtained by either vector. IHC analysis was done on
brain sections from age-matched untreated hetero-
zygousmice (Fig. 5D andH) for comparison with the
GM2 levels in an unaffected brain. From these ex-
periments, we conclude that delivery of scAAV9/
UsP-HEXM results in clearance of long-standing
GM2 accumulations, at least as well as that after
delivery of scAAV9/UsP-HEXA.
Intravenous administration of AAV9.47/
HEXM vector into neonatal Tay-Sachs mice
results in long-term CNS reduction
in GM2 gangliosides
Injections of AAV9.47/UsP-HEXM (at a dose of
5 ·1010 VG, through the facial vein) into neonatal
TSD mice on P0–P2 were done; the mice included
both knockout and heterozygous mice and were
Figure 4. Vector biodistribution and immunohistochemical analysis after intravenous administration of scAAV9.47/UsP-GFP in neonatal Tay-Sachs mice. Tay-
Sachs mice, both knockout (KO) and heterozygous (het), were injected via the facial vein on postnatal days 0–2 (P0–P2) with 5· 1010 VG of scAAV9.47/UsP-GFP and
analyzed 15 months postinjection. (A) qPCR biodistribution of GFP vector genomes in major organs in two heterozygous and two KO mice. (B) IHC images from
various regions of the brain from a Tay-Sachs disease (TSD) KO mouse showing GFP expression. Scale bar: 500lm. Insets: An additional· 5 magnification.
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euthanized when 15 months old. The pattern of
vector genome biodistribution whenHEXMwas the
transgene was variable between individual mice
but overall similar to the biodistribution pattern
whenGFPwas the transgene (Fig. 6A; comparewith
Fig. 4A). Biochemical analysis of both rostral and
caudal parts of the brain from treatedmice showed a
reduction in the accumulation of GM2 gangliosides
compared with that of control uninjected TSD mice
(Fig. 6B). The caudal (hind) brain had a more
marked quantitative reduction in GM2 storage than
the rostral brain (data not shown). This demon-
strates the ability of the scAAV9.47/UsP-HEXM
vector to mediate sustained reduction in CNS GM2
gangliosides, the hallmark of TSD pathology.
DISCUSSION
This paper addresses several challenges in cre-
ating an ideal gene replacement therapy for the
related Tay-Sachs and Sandhoff diseases. Past
studies have relied on single-stranded (ss)AAV,
herpes simplex virus, or adenoviral vectors ad-
ministered intracranially, to deliver a single
Hex subunit with one vector or both subunits by a
dual-vector approach.7–10,12,14,37–41 One challenge
is that the functional HexA enzyme consists of the
a- and b-subunits, which from a gene transfer per-
spective complicates a simple gene replacement
strategy because overexpression of one subunit will
inevitably lead to the other endogenous subunit
becoming rate-limiting. The HEXM gene, which
Figure 5. HexM is capable of reducing long-standing GM2 in aged Tay-Sachs mice. Fifteen-month-old TS knockout mice received a single unilateral
intracranial injection of a two-vector mixture containing equal amounts of scAAV9/UsP-GFP and scAAV/UsP-HEXA or scAAV9/UsP-HEXM. They were killed 4
weeks postinjection and coronal sections of the brain were analyzed by IHC for GFP expression to indicate the spread of vector (A–D) and GM2 accumulation
to assess the relative b-hexosaminidase activity (E–H). Sections from the brain of an uninjected heterozygous mouse from the TS mouse colony were used as
negative controls for both GFP expression and GM2 accumulation. The left side of mice was injected in (A–C) and (E–G). The vector mixtures used are
indicated on the left-hand side.
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encodes the modified Hex a-subunit variant, l,
overcomes this challenge because theHex l-subunit
can form a stable homodimer, HexM, which func-
tionally replaces the HexA heterodimer.28 Over-
expression of HexM has been shown to result in its
enhanced secretion, and secreted HexM is taken up
by other deficient cells through plasma membrane
mannose 6-phosphate receptors. In addition, unlike
HexA, both active sites in the HexMhomodimer can
potentially bind the GM2AP–GM2 complex and hy-
drolyze GM2. Thus, overexpression of HexM should
exert a greater therapeutic benefit through cross-
correction than would be possible through over-
expression of either the a- or b-subunit alone, which
would result predominantly in the secretion of ei-
ther HexS or HexB, respectively. Furthermore, the
HEXM gene can be packaged within a single scAAV
vector, eliminating the need for a relatively ineffi-
cient dual-vector approach.
The HEXA and HEXB genes are each approxi-
mately 1.6kb in length. Packaging them both within
a single AAV vector is theoretically possible using
traditional ssAAV vectors, but impossible within an
scAAV vector. Strategies to achieve widespread CNS
gene transfer in rodents, pigs, cats, dogs, and non-
human primates have been described using AAV9,
AAVrh10, and AAVrh8 vectors administered either
intravenously or into the CSF, but these strategies
rely on the more efficient scAAV.16–19,21,34,42–49 The
1.6-kb size of theHEXM gene could potentially allow
the HEXM gene to be packaged within an scAAV
vector, making such a vectormore amenable to these
approaches for widespread CNS gene transfer. The
selection of small promoters and poly(A) signals
to package a 1.6-kb gene within the approximately
2.2-kb packaging constraints of scAAV is quite lim-
ited, so we employed a novel synthetic promoter–
intron combination (UsP) based on the previously
Figure 6. Intravenous administration of AAV9.47/UsP-HEXM in neonatal Tay-Sachs mice results in long-term reduction in GM2 ganglioside levels. Tay-Sachs
mice, both knockout and heterozygous, were injected via the facial vein on P0–P2 with 5· 1010 VG of scAAV9.47/UsP-HEXM and analyzed 15 months
postinjection. (A) Vector biodistribution of scAAV9.47/UsP-HEXM in major organs from two KO and three heterozygous TSD mice. (B) The mean GM2-to-total
gangliosides ratio in the hindbrain region for neonatally injected HEXM (n= 4) and uninjected KO control (n = 2) mice. Error bars indicate the SEM.
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described synthetic JeT promoter,33 to provide a
moderate level of expression when combined with
theSV40poly(A) signal.WhendrivingGFP, theUsP
construct displays similar ubiquitous expression
throughout the CNS compared with the previously
described CBh promoter,22 although expression in
astrocytes appears diminished somewhat. We con-
clude that the UsP promoter–intron, combined with
the SV40 poly(A) signal, provides an ideal expres-
sion construct forHEXM within an scAAV vector.
A potential challenge related to intravenous ad-
ministration of AAV vectors (AAV9, AAVrh10, or
AAVrh8) targeting the CNS is that the high vector
doses required also result in extraordinarily high
loads of gene transfer to the liver. This creates
the potential for deleterious liver-specific T cell re-
sponses,50,51 possible toxicity related to transgene
overexpression, and hepatocellular carcinomawhen
administered toneonates.30,31Byusing theAAV9.47
capsid, biodistribution to the liver was highly re-
duced relative to AAV9, while preserving the ability
of AAV9 to cross the blood–brain barrier. An ap-
parent reduction in astrocyte transduction with
AAV9.47 was noted relative to AAV9, which may
necessitate a slightly higher overall dose. However,
in diseases that benefit from cross-correction, pri-
mary expression in neurons should be sufficient.
Regarding the potential for hepatocellular carci-
noma, our use of an enhancer-less expression con-
struct would be expected to reduce the potential for
oncogenesis.Whether as a result of the reduced liver
biodistribution or the lack of an enhancer, our co-
horts injected intravenously as neonates did not
develop tumors up to their planned end point of 15
months old. Although this observation should be
examinedmore carefully, it is encouraging.The time
course of infantile TSD and SD in humans is rapid,
and theearliest possible ageof interventionwouldbe
ideal. Although it is unclear whether the risk of he-
patocellular carcinomawith AAV vector observed in
mice could translate to humans, our vector design
potentially reduces that hypothetical risk.
The efficacy of gene therapy in mouse and cat
models of GM2 gangliosidosis is susceptible to misin-
terpretation because of the sialidase metabolic by-
pass pathway, which could significantly reduce GM2
storage levels with any increase in hexosaminidase
activity (i.e., HexA, HexB, HexS, or HexM). This by-
pass pathway does not exist in humans. The studies
reported here were conducted in the TSD model,
which is not ideal to evaluate treatment efficacy be-
cause of the mild phenotype of the mice. This paper
provides information on the development of the re-
agents, along with evidence supporting the hypothe-
sis that thishasa likelihoodofprovidinga therapeutic
benefit. A companion article by Osmon and col-
leagues,52 in this issue of Human Gene Therapy (see
p. 497), describes the application of this approach and
vector design with a mouse model of SD, which does
display a severe disease phenotype, and is more ap-
propriate for evaluating treatment efficacy.
Several technological advances were combined to
generate a reagent to treat Tay-Sachs and Sandhoff
diseases. This single scAAV vector design enables
delivery approaches for widespread CNS gene
transfer. Key to making use of scAAV are the novel
hexosaminidase variant, HEXM, and the short
synthetic promoter–intronUsP. Finally, byusing an
enhancerless expression construct and a liver-
detargeted capsid, we suggest that the possible risk
of hepatocellular carcinoma with this vector design
would be greatly diminished. In conclusion, the col-
lective body of work presented herein describes a
novel vector design that greatly enhances the po-
tential success of a gene transfer strategy to treat
both Tay-Sachs and Sandhoff diseases. This vector
design may also be useful to deliver other genes of
similar size to treat CNS disorders.
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